Today, Eli Lilly reported that the results of their Phase 3 study of olaratumab (LARTRUVO®) in combination with doxorubicin versus doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma showed no difference in survival between the study arms. Lilly news release.

“This is very discouraging news as we were hopeful this study would confirm their earlier positive trial results. This outcome underscores the importance of clinical research and patient participation so we understand the benefits or lack thereof of new treatments. We need to work together to find new and better treatments to improve outcomes for patients with sarcoma,” said Denise Reinke, SARC President and CEO.

Back to top